Three decades of glucose‐lowering therapy in patients at high cardiovascular risk — A real‐world analysis
These real-world data emphasize a marked shift in T2DM treatment towards novel substance classes. However, the use of incretin mimetics remained low. Significantly more patients reached HbA1c targets in the most recent cohort.
Authors
- Axel Muendlein (ORCID: https://orcid.org/0000-0002-5582-4125)
- ARTHUR MADER (ORCID: https://orcid.org/0000-0002-4897-2955)
- Alexander Vonbank (ORCID: https://orcid.org/0000-0001-5648-5623)
- MAGDALENA NEYER (ORCID: https://orcid.org/0009-0007-8962-0749)
- JOHANNES VOGEL (ORCID: https://orcid.org/0009-0009-5443-860X)
- PASCAL ELSNER (ORCID: https://orcid.org/0009-0000-2704-1572)
- Andreas Leiherer (ORCID: https://orcid.org/0000-0003-3776-5704)
- Heinz Drexel (ORCID: https://orcid.org/0000-0002-4677-9756)
- Andreas Festa
- Christoph H. Saely (ORCID: https://orcid.org/0000-0002-4226-4982)
- Heike Kuehrer
Institutions
- Landeskrankenhaus Feldkirch (AT)
- Private University in the Principality of Liechtenstein (LI)
- Vorarlberg Institute for Vascular Investigation and Treatment (AT)
- Drexel University (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1111/dom.16084
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07